Oxane HD and retinal detachment surgery in routine clinical practice.
OBJECTIVE
To assess the outcomes and complications of endotamponade with Oxane HD following retinal detachment repair.


METHODS
Retrospective consecutive case series of inferior retinal detachment with Oxane HD endotamponade within a 3-year period.


RESULTS
Case notes for 18 eyes of 18 patients were reviewed. Four (22.2%) were total retinal detachments and 13 (72.2%) had proliferative vitreoretinopathy. The mean Oxane HD endotamponade and follow-up durations were 27 ± 38 and 66 ± 39 weeks, respectively. The eventual anatomic success rate was 77.8%, but without any significant difference in vision. Postoperative complications occurred in 14 (77.8%), including emulsification (6 eyes; 33.3%), epiretinal membrane (5 eyes; 27.8%), and posterior capsular opacification (4 eyes; 22.2%). Of the 14 eyes requiring intraoperative perfluorodecalin, 12 (85.7%) developed complications; all 5 (100%) eyes with direct exchange of perfluorodecalin with Oxane HD developed complications.


CONCLUSIONS
Although useful for inferior retinal detachments, Oxane HD was associated with a relatively high rate of emulsification when compared to other series. Our series also suggests that prior use of perfluorodecalin intraoperatively, and in particular direct exchange of perfluorodecalin with Oxane HD, may be associated with an increased risk of intraocular complications.
Ang
Ghee Soon
GS
Department of Ophthalmology, Aberdeen Royal Infirmary, Aberdeen, UK.
Murphy
Anna Louise
AL
Ng
Wai Siene
WS
Atta
Hatem Riad
HR
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005466:Fluorocarbons / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D012163:Retinal Detachment / Q000150:complications / Q000503:physiopathology / Q000601:surgery*; D012189:Retrospective Studies; D018570:Risk Assessment; D012827:Silicone Oils / Q000008:administration & dosage*; D016896:Treatment Outcome; D014792:Visual Acuity; D014821:Vitrectomy / Q000009:adverse effects / Q000379:methods*; D018630:Vitreoretinopathy, Proliferative / Q000150:complications; D014822:Vitreous Body; D055815:Young Adult
D005466:Fluorocarbons; D012827:Silicone Oils; C539721:oxane HD; C008805:perfluorodecalin